Atrys Health S.A [ATRY] vs Oryzon Genomics S.A [ORY] Detailed Stock Comparison
Atrys Health S.A
BME
Loading...
Oryzon Genomics S.A
BME
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Atrys Health S.A wins in 8 metrics, Oryzon Genomics S.A wins in 9 metrics, with 0 ties. Oryzon Genomics S.A appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Atrys Health S.A | Oryzon Genomics S.A | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -6.67 | -47.70 | Oryzon Genomics S.A |
| Price-to-Book Ratio | 0.84 | 1.87 | Atrys Health S.A |
| Debt-to-Equity Ratio | 100.85 | 15.87 | Oryzon Genomics S.A |
| PEG Ratio | N/A | -16.24 | N/A |
| EV/EBITDA | 23.15 | -40.09 | Oryzon Genomics S.A |
| Profit Margin (TTM) | -14.57% | -56.48% | Atrys Health S.A |
| Operating Margin (TTM) | 3.20% | 6.30% | Oryzon Genomics S.A |
| EBITDA Margin (TTM) | 3.20% | 6.30% | Oryzon Genomics S.A |
| Return on Equity | -11.73% | -4.20% | Oryzon Genomics S.A |
| Return on Assets (TTM) | 0.20% | -2.52% | Atrys Health S.A |
| Free Cash Flow (TTM) | $-10.14M | $-13.40M | Atrys Health S.A |
| 1-Year Return | -17.88% | 77.84% | Oryzon Genomics S.A |
| Price-to-Sales Ratio (TTM) | 0.97 | 28.64 | Atrys Health S.A |
| Enterprise Value | $447.23M | $197.07M | Atrys Health S.A |
| EV/Revenue Ratio | 2.05 | 26.38 | Atrys Health S.A |
| Revenue per Share (TTM) | $3 | $0 | Atrys Health S.A |
| Earnings per Share (Diluted) | $-0.42 | $-0.06 | Oryzon Genomics S.A |
| Beta (Stock Volatility) | 0.63 | 0.43 | Oryzon Genomics S.A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Atrys Health S.A vs Oryzon Genomics S.A Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Atrys Health S.A | -3.21% | -2.52% | -5.90% | 5.86% | -13.69% | -22.57% |
| Oryzon Genomics S.A | -8.61% | 17.08% | 16.67% | 24.62% | 7.87% | 119.33% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Atrys Health S.A | -17.88% | -54.83% | -63.87% | 69.38% | 69.38% | 69.38% |
| Oryzon Genomics S.A | 77.84% | 56.67% | 13.45% | -7.32% | -7.32% | -7.32% |
News Based Sentiment: Atrys Health S.A vs Oryzon Genomics S.A
Atrys Health S.A
News based Sentiment: MIXED
September brought a mixed bag for Atrys Health, with revenue growth in key areas like oncology and diagnostics being overshadowed by a continued net loss and a high debt-to-equity ratio. While analysts remain optimistic with a 'BUY' rating and significant price target upside, the company's valuation and profitability remain key concerns for investors.
Oryzon Genomics S.A
News based Sentiment: POSITIVE
September was a pivotal month for Oryzon Genomics, characterized by a strategic expansion into the sickle cell disease market, a successful capital raise, and strengthening of its intellectual property portfolio. These developments significantly enhance the company's growth prospects and investor confidence, making it a noteworthy month for the company.
Performance & Financial Health Analysis: Atrys Health S.A vs Oryzon Genomics S.A
| Metric | ATRY | ORY |
|---|---|---|
| Market Information | ||
| Market Cap | €213.29M | €217.81M |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 21,792 | 223,440 |
| 90 Day Avg. Volume | 16,963 | 323,774 |
| Last Close | €2.71 | €3.29 |
| 52 Week Range | €2.48 - €3.79 | €1.40 - €3.69 |
| % from 52W High | -28.50% | -10.84% |
| All-Time High | €11.25 (Aug 30, 2021) | €5.25 (Dec 14, 2015) |
| % from All-Time High | -75.91% | -37.33% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.03% |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.15% | -0.56% |
| Operating Margin (TTM) | 0.03% | 0.06% |
| Return on Equity (TTM) | -0.12% | -0.04% |
| Debt to Equity (MRQ) | 100.85 | 15.87 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €3.33 | €1.47 |
| Cash per Share (MRQ) | €0.28 | €0.40 |
| Operating Cash Flow (TTM) | €3.00M | €-3,027,877 |
| Levered Free Cash Flow (TTM) | €-6,457,875 | €-10,217,728 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Atrys Health S.A vs Oryzon Genomics S.A
| Metric | ATRY | ORY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -6.67 | -47.70 |
| Forward P/E | 30.99 | -16.24 |
| PEG Ratio | N/A | -16.24 |
| Price to Sales (TTM) | 0.97 | 28.64 |
| Price to Book (MRQ) | 0.84 | 1.87 |
| Market Capitalization | ||
| Market Capitalization | €213.29M | €217.81M |
| Enterprise Value | €447.23M | €197.07M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.05 | 26.38 |
| Enterprise to EBITDA | 23.15 | -40.09 |
| Risk & Other Metrics | ||
| Beta | 0.63 | 0.43 |
| Book Value per Share (MRQ) | €3.33 | €1.47 |
Financial Statements Comparison: Atrys Health S.A vs Oryzon Genomics S.A
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ATRY | ORY |
|---|---|---|
| Revenue/Sales | N/A | €0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | €784,261 |
| Operating Income (EBIT) | N/A | €537,748 |
| EBITDA | N/A | €928,484 |
| Pre-Tax Income | N/A | €-1.41M |
| Income Tax | N/A | €-1.51M |
| Net Income (Profit) | N/A | €101,707 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ATRY | ORY |
|---|---|---|
| Cash & Equivalents | €20.37M | €31.11M |
| Total Current Assets | €89.18M | €34.14M |
| Total Current Liabilities | €99.79M | €13.01M |
| Long-Term Debt | €195.93M | €5.05M |
| Total Shareholders Equity | €253.24M | €114.22M |
| Retained Earnings | €-31.77M | €-20.93M |
| Property, Plant & Equipment | €10.31M | €1.08M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ATRY | ORY |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ATRY | ORY |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 21,792 | 223,440 |
| Average Daily Volume (90 Day) | 16,963 | 323,774 |
| Shares Outstanding | 75.92M | 64.75M |
| Float Shares | 41.85M | 61.35M |
| % Held by Insiders | 0.55% | 0.21% |
| % Held by Institutions | 0.05% | 0.04% |
Dividend Analysis & Yield Comparison: Atrys Health S.A vs Oryzon Genomics S.A
| Metric | ATRY | ORY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |